The importance of low-density lipoprotein (LDL) cholesterol in the development of atherosclerosis has long been recognized, and LDL cholesterol remains the primary target of therapy for the prevention of coronary heart disease. Nevertheless, increasing research attention over the past decade has been devoted to the heterogeneity of LDL particles and the atherogenicity of lipids and lipoproteins...

A raised low-density lipoprotein (LDL) cholesterol (LDL-C) is one of the major risk factors for ath-erosclerotic cardiovascular disease (ASCVD) 1-3). Homozygous family hypercholesterolemia (HoFH) is a rare inherited disease characterized by markedly elevated levels of LDL-C, generally more than 500 mg/ dL when untreated, and a high risk of premature ASCVD 4). HoFH is caused by loss-of-function ...

Omega-3 fatty acids have been shown to lower plasma cholesterol and triglyceride concentrations in humans. However, the effects of these fatty acids on the interactions among lipid concentrations, platelet activity, and atherogenesis have not been characterized in humans or in animals with low density lipoprotein (LDL) receptor deficiencies. To test the hypothesis that omega-3 fatty acids exert...

The atherogenic lipoprotein phenotype (ALP) is a common heritable trait characterized by a predominance of small, dense low density lipoprotein (LDL) particles (subclass pattern B), increased levels of triglyceride-rich lipoproteins, reductions in high density lipoprotein, and a 3-fold increased risk of myocardial infarction. Significant two-point linkage was found between ALP and the LDL recep...

Ischemic heart disease is the main cause of death worldwide and it is accelerated by increased low-density lipoprotein (LDL) cholesterol (LDL-C) and/or lipoprotein (a) (Lp(a)) concentrations. Proprotein convertase subtilisin/kexin type 9 (PCSK9) alters both LDL-C and in part Lp(a) concentrations through its ability to induce degradation of the LDL receptor (LDLR). PCSK9, however, has additional...

The anti-hypercholesterolemic effect of berbamine (BBM) isolated from Rhizoma Coptidis (RC) was investigated in hypercholesterolemic zebrafish model induced by high-cholesterol (HC) diet. Zebrafish embryo assay revealed no significant difference in morphology and cell death with the treatment of BBM less than 20 μg/mL. In zebrafish larvae, the fluorescently labeled cholesterol in caudal artery ...

The purpose of this study was to determine whether lovastatin treatment reduced very low density lipoprotein (VLDL) abnormalities in hypertriglyceridemic subjects. Lovastatin reduced plasma triglyceride levels and the levels of total VLDL, intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) cholesterol. The numbers of VLDL particles of Sf 100-400 and Sf 60-100 but not Sf 2...

background: dyslipidemia is considered an independent risk factor for coronary heart disease (chd). in the present study, we examined lipid profiles and paraoxonase 1 (pon1) activity and atherogenic indexes status and the relationship of pon1 activity by high-density lipoprotein (hdl) and atherogenic indexes in chd patients and healthy people. methods: the aim of the study was to compare pon1, ...

Low-density-lipoprotein (LDL) receptor family members control diverse developmental and physiological pathways. In this issue of Cell, both Culi and Mann and Hsieh et al. report on Boca/MESD, a highly conserved chaperone required for transport of LDLR family proteins to the cell surface. Together with recent insights into the atomic structure of the LDL receptor, they shed new light on the synt...

Hyperlipoproteinemia is one of the phenotypic characteristics of the fat Zucker rat that carries a mutation in the leptin receptor gene. In the present study, we studied the regulation of hepatic low density lipoprotein (LDL) receptor expression in lean and fat Zucker rats. Compared with lean rats, the fat ones had a pronounced (approximately 60%) reduction in hepatic LDL receptor expression, w...